Post-traumatic stress disorder, also known as PTSD, is a neuropsychiatric condition. Each year, roughly 5% of the US population is affected by the disorder.
The gold standard treatment, trauma-focused psychotherapy, does not yield desirable results as patients have persistent symptomology as well as high drop-out rates. Moreover, the FDA has approved several selective serotonin reuptake inhibitors, a.k.a. SSRIs, for the treatment of PTSD. Unfortunately, 35–47% of patients don’t respond to these medications.
Therefore, a new form of psychotherapy is necessary.